Gilead Sciences, Inc. (LON:0QYQ)

London flag London · Delayed Price · Currency is GBP · Price in USD
115.08
-2.18 (-1.86%)
At close: Aug 22, 2025
-1.86%
Market Cap104.94B
Revenue (ttm)21.07B
Net Income (ttm)4.61B
Shares Outn/a
EPS (ttm)3.66
PE Ratio22.78
Forward PE13.51
Dividend2.39 (2.08%)
Ex-Dividend DateJun 13, 2025
Volume8,613
Average Volume6,015
Open116.80
Previous Close117.26
Day's Range115.08 - 117.85
52-Week Range75.35 - 121.83
Beta0.35
RSI48.13
Earnings DateAug 1, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1987
Employees 17,600
Stock Exchange London Stock Exchange
Ticker Symbol 0QYQ
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements

News

There is no news available yet.